DIALYBRID
Cantu
About DIALYBRID
Dialybrid provide product that include silkothane arteriovenous graft, SAG biomimetic nanostructure, and situ tissue engineering products. Their proprietary innovative technology, silkothane, is a hybrid material combining silk fibroin and polyurethane. Their aim is to develop a novel semi-degradable vascular access for hemodialysis.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $356.2K
- Funding stage: Seed
- Last round: Seed (Jul 2020)
- Website: dialybrid.com
- Phone: +39 031 7377739
Industries & Categories
Biotechnology, Finance, Medical
Canonical: https://fsome.com/organization/dialybrid-149198 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.